Search Results

IMIDomics Inc. today announced a strategic license and collaboration agreement with the University of Barcelona (UB).

IMIDomics announced today that it is expanding its strategic collaboration with Bristol Myers Squibb, a global biopharmaceutical company.

IMIDomics Inc. today announced that it has entered into an agreement with WuXi Biologics, a global Contract Research, Development and Manufacturing Organization, aimed at accelerating the development and manufacturing of IMIDomics IMB1001.

Twist Bioscience Corporation and IMIDomics, Inc. today announced a multi-program collaboration whereby Twist will utilize its antigen development capabilities and Library of Libraries to conduct antibody discovery activities against targets identified by IMIDomics.

IMIDomics proudly announces the addition of Dr. Eric Perakslis, a highly accomplished pharmaceutical R&D and digital sciences executive, as Senior Vice President and Chief Technology Officer (CTO).

IMIDomics Inc., a patient-centric drug discovery and development company focused on Immune-Mediated Inflammatory Diseases (IMIDs), today announced an exclusive license agreement with TNAX Biopharma Corporation (TNAX), an innovator in biotechnology.

IMIDomics, Inc. announced the formation of an Immunology Advisory Board consisting of a number of scientific and industry luminaries with experience in developing and bringing to market new therapies targeting IMIDs.

IMIDomics Inc., a global biotechnology company focused on the discovery and development of new medicines for the treatment of patients with immune-mediated inflammatory diseases, announced the formation and members of its Scientific Advisory Board and Business Advisory Board.

IMIDomics, Inc., a privately held global biotechnology company focused on the discovery and development of new targets and medicines for the treatment of patients with immune-mediated inflammatory diseases (IMIDs), announced today that Evotec SE (FSE: EVT; MDAX/TecDAX, ISIN: DE0005664809; NASDAQ: EVO) has made an equity investment in the company.